Fei Baowei, Wang Hesheng, Meyers Joseph D, Feyes Denise K, Oleinick Nancy L, Duerk Jeffrey L
Department of Radiology, Case Western Reserve University & University Hospitals Case Medical Center, Cleveland, Ohio, 44106, USA.
Lasers Surg Med. 2007 Oct;39(9):723-30. doi: 10.1002/lsm.20576.
High-field magnetic resonance imaging (MRI) is an emerging technique that provides a powerful, non-invasive tool for in vivo studies of cancer therapy in animal models. Photodynamic therapy (PDT) is a relatively new treatment modality for prostate cancer, the second leading cause of cancer mortality in American males. The goal of this study was to evaluate the response of human prostate tumor cells growing as xenografts in athymic nude mice to Pc 4-sensitized PDT.
PC-3, a cell line derived from a human prostate malignant tumor, was injected intradermally on the back flanks of athymic nude mice. Two tumors were initiated on each mouse. One was treated and the other served as the control. A second-generation photosensitizing drug Pc 4 (0.6 mg/kg body weight) was delivered to each animal by tail vein injection 48 hours before laser illumination (672 nm, 100 mW/cm(2), 150 J/cm(2)). A dedicated high-field (9.4 T) small-animal MR scanner was used for image acquisitions. A multi-slice multi-echo (MSME) technique, permitting noninvasive in vivo assessment of potential therapeutic effects, was used to measure the T2 values and tumor volumes. Animals were scanned immediately before and after PDT and 24 hours after PDT. T2 values were computed and analyzed for the tumor regions.
For the treated tumors, the T2 values significantly increased (P<0.002) 24 hours after PDT (68.2+/- 8.5 milliseconds), compared to the pre-PDT values (55.8+/-6.6 milliseconds). For the control tumors, there was no significant difference (P = 0.53) between the pre-PDT (52.5+/-6.1 milliseconds) and 24-hour post-PDT (54.3+/-6.4 milliseconds) values. Histologic analysis showed that PDT-treated tumors demonstrated necrosis and inflammation that was not seen in the control.
Changes in tumor T2 values measured by multi-slice multi-echo MR imaging provide an assay that could be useful for clinical monitoring of photodynamic therapy of prostate tumors.
高场磁共振成像(MRI)是一种新兴技术,为动物模型中癌症治疗的体内研究提供了一种强大的非侵入性工具。光动力疗法(PDT)是前列腺癌的一种相对较新的治疗方式,前列腺癌是美国男性癌症死亡的第二大主要原因。本研究的目的是评估在无胸腺裸鼠体内异种移植生长的人前列腺肿瘤细胞对Pc 4敏化光动力疗法的反应。
将源自人前列腺恶性肿瘤的PC-3细胞系皮内注射到无胸腺裸鼠的后胁腹。每只小鼠接种两个肿瘤。一个进行治疗,另一个作为对照。在激光照射(672 nm,100 mW/cm²,150 J/cm²)前48小时,通过尾静脉注射将第二代光敏药物Pc 4(0.6 mg/kg体重)给予每只动物。使用专用的高场(9.4 T)小动物MR扫描仪进行图像采集。采用多切片多回波(MSME)技术测量T2值和肿瘤体积,该技术可对潜在治疗效果进行非侵入性体内评估。在光动力疗法前后及光动力疗法后24小时对动物进行扫描。计算并分析肿瘤区域的T2值。
对于治疗后的肿瘤,光动力疗法后24小时的T2值(68.2±8.5毫秒)与光动力疗法前的值(55.8±6.6毫秒)相比显著增加(P<0.002)。对于对照肿瘤,光动力疗法前(52.5±6.1毫秒)和光动力疗法后24小时(54.3±6.4毫秒)的值之间无显著差异(P = 0.53)。组织学分析表明,光动力疗法治疗的肿瘤出现了对照中未见的坏死和炎症。
通过多切片多回波MR成像测量的肿瘤T2值变化提供了一种可用于临床监测前列腺肿瘤光动力疗法的检测方法。